Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line

Abroad (travel likely)RecruitingPHASE3

Conditions

Diffuse Large B Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CHU Jean Minjoz, Besançon, France
Contact: Study coordinator (Adrien CHAUCHET, MD) · achauchet@chu-besancon.fr · 0381669024
Contact: Principal Investigator (Adrien CHAUCHET)
Clinique Victor Hugo / Centre Jean Bernard, Le Mans, France
Contact: Study coordinator (Katell LE DÛ, MD) · k.ledu@cjb72.org · 0243391300
Contact: Principal Investigator (Katell LE DÛ, MD)
CHRU Nancy, Nancy, France
Contact: Study coordinator (Pierre FEUGIER, MD) · p.feugier@chru-nancy.fr · 0383153282
Contact: Principal Investigator (Pierre FEUGIER, MD)
Hôpital Privé du Confluent, Nantes, France
Contact: Study coordinator (Sophie LEBOUVIER-SADOT, MD) · sophie.sadot.lebouvier@groupeconfluent.fr · 0228272118
Contact: Principal Investigator (Sophie LEBOUVIER-SADOT, MD)
CH Perpignan, Perpignan, France
Contact: Study coordinator (Virginie ROLAND, MD) · virginie.roland@ch-perpignan.fr · 0468618907
Contact: Principal Investigator (Virginie ROLAND, MD)

Study leads

Katell LE DÛ, MD
Principal Investigator
Clinique Victor Hugo/Centre Jean Bernard

View source on ClinicalTrials.gov Contact study team (email)